Low-density lipoprotein

There are 222 papers on low-density lipoprotein in aging research: 32 trials and 106 observational studies in people, 18 in animals, 2 in cells, 56 reviews. The newest story, Nov 21, 2026: “Blood fat had an uncertain link to repeat cardiovascular events”.

Biomarker

222 papers study it2,656 more mention it57 findings

332 new papers in 30 daysSee all 2,878 papers on low-density lipoprotein

At a glance

Higher LDL is linked with degenerative valvular heart disease in a study of older adults and peripheral atherosclerosis in another human study. A trial in Hutchinson-Gilford progeria syndrome reports LDL lowering with lonafarnib. Other human trials report reductions with semaglutide and exercise, whereas an acarbose trial finds no clear effect.

57 findings in 53 papers from 2011 to 2026, 13 of them since April 2026

“there was no evidence of an association between genetically predicted lipid traits and SAH for LDL (HR 1.06 [0.64-1.73])”
Lipid Traits and Risk of Subarachnoid Haemorrhage: A Systematic Review and Mendelian Randomization Study in UK BiobankTranslational stroke research2026doi:10.1007/s12975-026-01499-6
  • Human trial32
  • Humans106
  • Animals18
  • Cells2
  • In silico3

Interventions

24

Wuqinxi

downin humans1

1 study
  1. Wuqinxi decreases low-density lipoprotein in middle-aged and older adults with primary hypertension (SMD = -0.63, 95% CI: -1.19 to -0.07).

    Reviewin middle-aged and older adults with primary hypertension3-6 months

More on Wuqinxi

Multimodal non-hormonal intervention

downin humans1

1 study
  1. Multimodal non-hormonal intervention decreases low-density lipoprotein in humans (p = 0.001-0.003).

    Human trial12 weeksfemalesn = 44

More on Multimodal non-hormonal intervention

Lonafarnib

downin humans1

1 study
  1. Lonafarnib decreases low-density lipoprotein in humans (Hutchinson-Gilford progeria syndrome) (2.8 (2.3, 3.5) vs. 2.5 (2.1, 2.8) mmol/L).

    Human trialHutchinson-Gilford progeria syndrome(7±2) monthsn = 10

More on Lonafarnib

Intermittent fasting

downin humans1

1 study
  1. Intermittent fasting decreases low-density lipoprotein in type 2 diabetes mellitus (MD -6.31, 95% CI -11.81 to -0.81).

    Reviewin type 2 diabetes mellitus

More on Intermittent fasting

Pili pasifika program

downin humans1

1 study
  1. Pili pasifika program decreases low-density lipoprotein in humans with ≥1 cardiometabolic risk factor (-4.7 vs +7.6 mg/dL).

    Human trialwith ≥1 cardiometabolic risk factor12 weekly sessionsn = 242

More on Pili pasifika program

Resveratrol

downin humans1

1 study
  1. Resveratrol decreases low-density lipoprotein in humans (postoperative CABG patients).

    Human trialpostoperative CABG patientscapsules60 daysn = 60

More on Resveratrol

Caloric restriction

upin mice1

1 study
  1. Caloric restriction increases low-density lipoprotein in mice (ApoE/LDLr-/-).

    AnimalsApoE/LDLr-/-8 weeksmales

More on Caloric restriction

Combined aerobic and resistance training

downin humans1

1 study
  1. Combined aerobic and resistance training decreases low-density lipoprotein in humans (hypertension) (p < 0.05 and p < 0.001).

    Reviewhypertension

More on Combined aerobic and resistance training

Nordic walking

downin humans1

1 study
  1. Nordic walking decreases low-density lipoprotein in humans (SMD = -0.27, 95 % CI [-0.43; -0.12], p < 0.01).

    Reviewn = 1,271

More on Nordic walking

Semaglutide

downin humans1

1 study
  1. Semaglutide decreases low-density lipoprotein in humans (versus placebo) (mean difference -0.16 mmol/L (95% CI -0.30 to -0.02)).

    Human trialversus placebo

More on Semaglutide

GLP-1 receptor agonists

downin humans1

1 study
  1. GLP-1 receptor agonists decrease low-density lipoprotein in humans (individuals with obesity without diabetes) (SMD -0.27 mg/dL; P <.01).

    Human trialindividuals with obesity without diabetes

More on GLP-1 receptor agonists

Acarbose

no changein humans1

1 study
  1. Acarbose showed no clear effect on low-density lipoprotein in humans.

    Human trialn = 7,046

More on Acarbose

Fermented black soybean koji product

downin humans1

1 study
  1. Fermented black soybean koji product decreases low-density lipoprotein in humans (early sarcopenia).

    Human trialearly sarcopenia10 weeksn = 46

More on Fermented black soybean koji product

Astaxanthin

downin humans1

1 study
  1. Astaxanthin decreases low-density lipoprotein in humans (prediabetes and dyslipidaemia) (-0.33 ± 0.11 mM, P < .05).

    Human trialprediabetes and dyslipidaemia12 mg daily24 weeks

More on Astaxanthin

Levocarnitine

downin humans1

1 study
  1. Levocarnitine decreases low-density lipoprotein in women with PCOS.

    Human trialin women with PCOSPursinapharma, Iran3 g dailythree monthsfemales

More on Levocarnitine

All 24

Effects

4

Subarachnoid hemorrhage

no changein humans1HR 1.06

1 study
  1. Low-density lipoprotein was not clearly linked with subarachnoid hemorrhage in humans (Genetically predicted lipid trait; analysis adjusted for lipid-lowering therapy) (HR 1.06 [0.64-1.73]).

    HumansGenetically predicted lipid trait; analysis adjusted for lipid-lowering therapyn = 486,603

More on Subarachnoid hemorrhage

Mortality

no changein humans1HR 1.06

1 study
  1. Low-density lipoprotein was not clearly linked with mortality in humans (hip fracture, LDL > 2.31 mmol/L) (HR = 1.06, 95%CI: 0.70, 1.63, p = 0.7722).

    Humanship fracture, LDL > 2.31 mmol/Lmean follow-up of 34.17 monthsn = 339

Amyotrophic lateral sclerosis

mediatesin humans1

1 study
  1. Low-density lipoprotein is linked with amyotrophic lateral sclerosis in humans.

    Humansindirect effect of leukocyte telomere length, European population; total cholesterol also named as mediator

More on Amyotrophic lateral sclerosis

Dry eye disease symptoms

no changein humans1

1 study
  1. Low-density lipoprotein was not clearly linked with dry eye disease symptoms in humans.

    Humans

Upstream

2

Age at menarche

downin humans1OR 0.814

1 study
  1. Age at menarche is linked with worse low-density lipoprotein in humans (OR = 0.814, 95% CI 0.693-0.956).

    Humanspostmenopausal women with established hyper-LDL cholesterolemia, late menarche vs 12-15 yearsfemales

More on Age at menarche

PPARG

downin mice1

1 study
  1. PPARG decreases low-density lipoprotein in Ldlr-/- background.

    Animalsin Ldlr-/- background

More on PPARG

Associations

26

Mortality

downin humans2HR 0.42

2 studies
  1. Low-density lipoprotein is associated with mortality in humans (hip fracture, LDL < 2.31 mmol/L) (HR = 0.42, 95%CI: 0.25, 0.69, p = 0.0006).

    Humanship fracture, LDL < 2.31 mmol/Lmean follow-up of 34.17 monthsn = 339

  2. Low-density lipoprotein is associated with mortality in the oldest-old.

    Reviewin the oldest-old

Lipid and ceramide metabolism

mixedin humans1

1 study
  1. Low-density lipoprotein is associated with lipid and ceramide metabolism in humans (Genetically determined variation assessed using Mendelian randomization).

    HumansGenetically determined variation assessed using Mendelian randomizationn = 46,000

More on Lipid and ceramide metabolism

Carotid artery calcification severity

mixedin humans1

1 study
  1. Low-density lipoprotein is associated with carotid artery calcification severity in humans (Patients with internal carotid artery sclerotic changes).

    HumansPatients with internal carotid artery sclerotic changesinternal carotid arteryn = 108

Health behavior patterns

mixedin humans1

1 study
  1. health behavior patterns are associated with low-density lipoprotein in Korean college students.

    Humansin Korean college studentsn = 417

Meibomian gland dropout

upin humans1

1 study
  1. Low-density lipoprotein predicts meibomian gland dropout in statin-treated patients with dyslipidemia (P < 0.050).

    Humansin statin-treated patients with dyslipidemia

Meiboscore

upin humans1

1 study
  1. Low-density lipoprotein is associated with meiboscore in statin-treated patients with dyslipidemia (r = 0.426, P = 0.001).

    Humansin statin-treated patients with dyslipidemia

More on Meiboscore

Arcus senilis

upin humans1

1 study
  1. Arcus senilis is associated with low-density lipoprotein in humans.

    Review

More on Arcus senilis

Microbial age

upin humans1

1 study
  1. Microbial age is associated with low-density lipoprotein in humans (high-risk individuals for diabetes) (P<.001).

    Humanshigh-risk individuals for diabetesn = 103

More on Microbial age

Waist circumference

upin humans1

1 study
  1. Waist circumference is associated with low-density lipoprotein in humans (r = 0.42, p = 0.003).

    Humansfemalesn = 60

More on Waist circumference

Renal resistive index

upin humans1

1 study
  1. Low-density lipoprotein is associated with renal resistive index in adults evaluated for CKD.

    Humansin adults evaluated for CKD

More on Renal resistive index

All 26

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Human studies associate LDL with meiboscore and meibomian gland dropout in statin-treated patients with dyslipidemia, and with health behavior patterns in Korean college students. A review describes LDL reductions with Wuqinxi in middle-aged and older adults with primary hypertension over 3–6 months.

  2. Summary written from the findings.

Latest

Preprints.org

Blood fat had an uncertain link to repeat cardiovascular events

Among patients with prior cardiovascular disease, five-year rates of major cardiovascular events were 20.1% with high lipoprotein(a), a fat-carrying blood particle…Among patients with prior cardiovascular disease, five-year rates of major cardiovascular events were 20.1% with high lipoprotein(a), a fat-carrying blood particle, versus 18.3% with low levels.

Preprint: cohort · 13,865 peopleCardiovascular disease

See all 2,878 papers on low-density lipoprotein